
CARGO offloads staff after abandoning lead CAR-T
Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
Newsletters and Deep Dive digital magazine
Less than 18 months after its IPO, CAR-T developer CARGO has abandoned its development efforts and slashed around 90% of its staff.
Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks